Hong Kong Shengda Pharmaceutical

Shengda Pharmaceutical is an international pharmaceutical company established in 2009, headquartered in Hong Kong with major operations in Shenzhen and Jiangxi, China. The company specializes in the research, development, and production of high-end pharmaceutical APIs and intermediates, with a strategic focus on targeted anti-tumor therapies. Shengda operates a multi-functional R&D center in Shenzhen and a GMP-compliant manufacturing base in Jiangxi, providing a full range of services from laboratory-scale synthesis to large-scale industrial production. Their product portfolio includes nearly a hundred varieties, including generic versions of advanced oncology drugs like Brigatinib and Lorlatinib, and they serve as a key CRO/CMO partner for global pharmaceutical companies.